作者
Yuan M Di, Chun Guang Li, Charlie Changli Xue, Shu-Feng Zhou
发表日期
2008/6/1
来源
Current pharmaceutical design
卷号
14
期号
17
页码范围
1723-1742
出版商
Bentham Science Publishers
简介
St. John's wort (Hypericum perforatum, SJW) is one of the most commonly used herbal antidepressants for the treatment of minor to moderate depression. A major safety concern about SJW is its ability to alter the pharmacokinetics and/or clinical response of a variety of clinically important drugs that have distinctive chemical structure, mechanism of action and metabolic pathways. This review highlights and updates the knowledge on clinical interactions of prescribed drugs with SJW and the implication in drug development. A number of clinically significant interactions of SJW have been identified with conventional drugs, including anticancer agents (imatinib and irinotecan), anti-HIV agents (e.g. indinavir, lamivudine and nevirapine), anti-inflammatory agents (e.g. ibuprofen and fexofenadine), antimicrobial agents (e.g. erythromycin and voriconazole), cardiovascular drugs (e.g. digoxin, ivabradine, warfarin, verapamil …
引用总数
200720082009201020112012201320142015201620172018201920202021202220232024216161715141611686553451
学术搜索中的文章